Raymond W. Cohen
Mr. Cohen has worked as an executive in the life sciences industry for over 30 years. Cohen is an accredited public company director and serves as a member of the board of directors of a number of private and publicly listed companies in the US and Europe. He currently serves as the CEO of Irvine, CA based Axonics Modulation Technologies Inc., a developer of implantable neuromodulation devices and as a director of Spectrum Pharmaceuticals Inc. (NASDAQ:SSPI), a biotechnology company; as Chairman of BioLife Solutions Inc. (NASDAQ: BLFS), a manufacturer and marketer of preservation media for human cells; as the independent director of LifeWatch AG (LIFE.SW), an ambulatory ECG service provider; as Chairman of Lombard Medical (NASDAQ:EVAR), a UK-based Nasdaq-listed manufacturer and marketer of endovascular aortic stent grafts; and as Chairman of Syncroness, Inc., a privately-held contract engineering and product development firm. From 2010 to 2012, Mr. Cohen served as the Chief Executive Officer and member of the Board of Directors of Vessix Vascular, Inc., a developer of a novel RF balloon catheter technology for treatment of hypertension that was acquired by Boston Scientific Corp. in November 2012. Previously, for nearly a decade, Mr. Cohen served as Chief Executive Officer of NASDAQ-listed, Irvine, California based, Cardiac Science, Inc., a manufacturer of automatic external defibrillators that was ranked by Deloitte as the 4th fastest growing company in North America in 2004.
Chief Executive Officer
Alastair has over 25 years of Product Marketing, Development, Manufacturing and Sales experience within both corporate and start-up environments. He joined DYSIS Medical from Optos plc where he served as the European General Manager, Global Product Director and was a member of the Senior Management team that floated the company on the main London market in 2006. Prior to joining Optos Mr Atkinson had an 18 year career with Hewlett Packard holding a number of national and international positions. He has a BSc from Reading University, an MSc from Bristol University and completed the Advanced Management Program at INSEAD.
Casper Breum was previously CEO of ilochip A/S, a venture backed company focused on development of diagnostic biochips. Before this he held different positions at H.Lundbeck A/S most recently in corporate business development and strategy where he gained broad international experience. He was also a member of the Board of Directors of the Lundbeck Foundation and Lundbeckfond Invest as an employee representative. Prior to his work at H.Lundbeck, Casper worked for Novo Nordisk A/S and Niels Clauson-Kaas A/S. Casper has an MSc in organic chemistry and an MBA.